5R,9R,13S,14R-hydrocodone salicylate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 5R,9R,13S,14R-hydrocodone salicylate
• 英文别名: (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;2-hydroxybenzoic acid
• 化学式: C₇H₆O₃*C₁₈H₂₁NO₃
• 分子量: 437.492
• InChiKey: YPJNOZAPMKHGJP-RNWHKREASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.02
• 重原子数：
  32
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  96.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  舒洛芬 、 5R,9R,13S,14R-hydrocodone bitartrate 以 水 为溶剂， 反应 1.0h， 生成 5R,9R,13S,14R-hydrocodone salicylate
  参考文献：
  名称：

  Narcotic-NSAID ion pairs

  摘要：

  本发明提供了一种公式为[narcotic]+[A]−的离子对化合物，其中[narcotic]+代表至少一个麻醉剂或其一个或多个立体化学异构体的至少一个阳离子，而[A]−代表至少一个非甾体抗炎药（NSAID）或其一个或多个立体化学异构体的至少一个阴离子。离子对化合物的一个例子是丙氧芬双氯芬酸。这些离子对化合物或其药物组合物在治疗表明需要镇痛剂、抗炎剂或两者都需要的方法中是有用的。在规定的使用条件下，离子对化合物在低pH环境中表现出较差或完全不溶性，但在胃中这类环境中却具有极佳的化学稳定性。离子对化合物在较高pH值的环境中，如小肠，能够快速溶解和离解，以释放组成的麻醉剂和非甾体抗炎药。

  公开号：

  US20050203115A1

文献信息

• BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF
  申请人：Mickle Travis

  公开号：US20110002990A1

  公开（公告）日：2011-01-06

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了包含芳基羧酸与羟考酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭形成的新型羟考酮前药/组合物，包括苯甲酸酯和杂环芳基羧酸，具有降低滥用羟考酮潜力的特性。该技术还提供了治疗患者的方法、制药工具包和合成本技术共轭物的方法。
• Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof
  申请人：KemPharm, Inc.

  公开号：US20150335759A1

  公开（公告）日：2015-11-26

  The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

  目前描述的技术提供了治疗患有中度至严重疼痛、麻醉药或阿片类药物滥用或戒断症状的患者的方法。目前描述的方法是通过向患者施用包含对乙酰氨基酚和苯甲酸盐羟考酮盐酸盐的药物有效量的组合物来实施的。与未结合的羟考酮相比，该组合物具有减少的副作用。
• Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
  申请人：Mickle Travis

  公开号：US20120142719A1

  公开（公告）日：2012-06-07

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了一种组合物，其中包括芳基羧酸与氢可酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭形成的新型氢可酮前药/组合物，包括苯甲酸酯和杂环羧酸，具有降低氢可酮滥用潜力的特点。该技术还提供了治疗患者的方法、药物工具包以及合成该技术共轭物的方法。
• Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Uses Thereof
  申请人：KemPharm, Inc.

  公开号：US20150065536A1

  公开（公告）日：2015-03-05

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前所描述的技术提供了化学共轭的芳基羧酸与氢可酮（吗啡酮，4,5-α-环氧-3-甲氧基-17-甲基）形成的新型前药/氢可酮组合物，包括苯甲酸酯和杂环羧酸，其具有降低滥用氢可酮的潜力。本技术还提供了治疗患者的方法、制药套件和合成本技术共轭物的方法。
• Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
  申请人：KemPharm, Inc.

  公开号：US10351573B2

  公开（公告）日：2019-07-16

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  本技术提供了由芳基羧酸与氢可酮（吗啡烷-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭以形成氢可酮的新型原药/组合物的组合物，包括苯甲酸酯和杂芳基羧酸，其滥用氢可酮的可能性降低。本技术还提供了治疗病人的方法、医药包和合成本技术共轭物的方法。